Journal of Clinical and Molecular Endocrinology

Effect of Genistein on Endometriosis Lesion, Matrix Metalloproteinase-2 and -9 Level of Endometriosis: In silico and In vivo Study

This in silico and in vivo investigation were to know the effect of genistein on alteration of MMPs in a mice model of endometriosis. Forty female mice (Mus musculus) were divided into eight groups (n=5 each), including the control (untreated) group, endometriosis group, and the endometriosis (EM) groups were given various doses of genistein (at dose of 50; 100; 200; 300; 400; 500 mg/day). In silico analysis was performed using Open Babel, 3D DART webserver, HEX software, and NUCPLOT software. Analysis of MMP-2 and MMP-9 level were done by enzyme linked immuno sorbent assay (ELISA) technically. In the absence of genistein, ΣE total required for the interaction between NF-?B with MMP-2 or MMP-9 gene promoter were increased in genistein treatment (-2393.71 kJ/mol and -2393.86 kJ/mol) compared with no genistein treatment (-2415.62 kJ/mol and -2457.00 kJ/mol). In endometriosis group we were founded the massive endometriosis lesion and hyper vascularization. All doses the treatment with genistein reduces the size of endometriosis lesion. The level of MMP-2 and MMP-9 was significantly higher in the EM group compared to the untreated control group (P<0.05). This increase in MMP-2 was significantly (P<0.05) attenuated by all doses of genistein. These increased levels of MMP-9 in the EM group were significantly reduced by 100 mg/day administration of genistein. In conclusion, genistein prohibits the increase in MMP-2 and MMP-9 in a mice model of endometriosis. Therefore, this may provide a natural therapy for attenuating the alteration of MMPs found in endometriosis disease.

Author(s):

Maharani Maharani, Endang Sri Wahyuni , Sutrisno Sutrisno

Abstract | Full-Text | PDF

Share this